Literature DB >> 11797118

Blastic NK-cell lymphoma/leukemia with T-cell receptor gamma rearrangement.

Y Aoyama1, T Yamane, M Hino, K Ohta, H Nakamae, R Yamamura, K R Koh, T Takubo, T Inoue, Y Tatsumi, N Tatsumi.   

Abstract

A 79-year-old Japanese man was admitted to our hospital with dyspnea in June 1999. Physical examination revealed general exanthema, hepatosplenomegaly, and lymphadenopathy. Increased numbers of abnormal cells were observed in peripheral blood; these cells were of lymphoblastic morphology with high nuclear/cytoplasm ratios and few azurophilic granules. Immunophenotypic analysis revealed positivity for CD2, CD4, CD56, and HLA-DR, and negativity for CD3, CD13, CD16, CD33, CD34, and T cell receptor (TCR). On genotypic analysis, TCRgamma chain was rearranged, but neither the TCRbeta chain nor TCRdelta chain. Despite an initial good response to chemotherapy the disease relapsed in the early stage, and the patient died 6 months after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11797118     DOI: 10.1007/s00277-001-0380-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

1.  CD4+CD56+ lineage negative hematopoietic neoplasm: so called blastic NK cell lymphoma.

Authors:  Yoonjung Kim; Mi Seon Kang; Chan Whan Kim; Rohyun Sung; Young H Ko
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

Review 2.  Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.

Authors:  Wei Cheng; Tian-Tian Yu; Ai-Ping Tang; Ken He Young; Li Yu
Journal:  Curr Med Sci       Date:  2021-07-03

Review 3.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.